Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: Within-trial results of the Indian Diabetes Prevention Programme (IDPP)

Diabetes Care

Volumn 30, Issue 10, 2007, Pages 2548-2552

  Ramachandran, Ambady ^a   Snehalatha, Chamukuttan ^a   Yamuna, Annasami ^a   Mary, Simon ^a   Ping, Zhang ^b  

^a Dr A Ramachandran's Diabetes Hospitals   (India)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

ADULT; COST OF ILLNESS; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; LIFE STYLE; MALE; MIDDLE AGED; PRIMARY PREVENTION;

EID: 35148827614     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0150     Document Type: Article

References (16)

1. Sicree R, Shaw J, Zimmet P: Diabetes and impaired glucose tolerance: part 1 - the global burden. In Diabetes Atlas, 3rd ed. Brussels, Belgium, International Diabetes Federation, 2006, p. 16-105
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. United Kingdom Prospective Diabetes Study Group (UKPDS 33): Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
4. Gilmer TP, O'Connor PJ, Manning WG, Rush WA: The cost to health plans for poor glycemic control. Diabetes Care 20:1847-1853, 1997
5. Herman WH: Economic analyses of diabetes interventions: rationale, principles, findings and interpretation. Endocrinologist 9:113-117, 1999
6. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V: The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289-297, 2006
7. Knowler WC, Barrett-Conner E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group.: Reduction in the incidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 346:393-403, 2002
8. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas N, Salminen V, Aunola S, Cepaitis Z, Moltchanov V, Hakumaki M, Mannelin M, Martikkala V, Sundvall J, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in life style among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
9. Eriksson KF, Lindgrade F: Prevention of type 2 (non insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 34:891-898, 1997
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
11. The Diabetes Prevention Program Research Group: Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care 26:36-47, 2003
12. The Diabetes Prevention Program Research Group: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26:2518-2523, 2003
13. Gold MR, Siegel JE, Russell LB, Weinstein MC, Eds: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1990
14. Renjilian DA, Perri MG, Nezu AM, McKelvey WF, Shermer RL, Anton SD: Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. J Consult Clin Psychol 45:288-298, 1977
15. Robert GJ, McGuire AJ, Gauri BS: A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. Int J Clin Pract 60:847-855, 2006
16. Ramachandran A, Shobhana R, Snehalatha C, Christina A, Murugesan N, Vijay V, Kapur A, Williams R: Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care 30:252-256, 2007